The invention generally relates to the treatment of cancer with FLT3 targetingagents and kinase inhibitors. In particular,the invention relates to adoptive immunotherapy of Acute Myeloid Leukemia(AML) with chimeric antigen receptor (CAR)-modifiedT cells specific for FMS-like tyrosine kinase (FLT3) in combination with FLT3inhibitors.